Clinical and echocardiographic outcomes of transcatheter mitral valve repair in atrial functional mitral regurgitation
Introduction
Mitral regurgitation (MR) has been traditionally classified as primary or secondary depending on the etiology of the valvular disease [1]. Primary MR (PMR) is due to the organic disease of the mitral valve (MV) leaflets and myxomatous degeneration is the most common cause. On the contrary, secondary MR, also known as functional MR (FMR), is related to the dilatation of the MV annulus (MVA) and/or the dysfunction of the subvalvular apparatus in patients with normal MV leaflets. To date, FMR mainly referred to the restriction of the MV leaflets' movement caused by the remodeling of one or both papillary muscles in patients with ischemic heart disease (IHD) or dilated cardiomyopathy. Therefore, FMR is commonly used as a synonymous of left ventricular (LV) MV disease.
Nevertheless, in the last years, a new type of FMR has been described associated to the dilatation of the MVA in patients with preserved LV function and long-standing atrial fibrillation (AF) [2]. Despite the high prevalence and frequent coexistence of both, MR and AF, very little is known about prognosis and outcomes after different therapeutic strategies of the so-called atrial FMR (AFMR) [3]. Randomized trials and several registries have proved the safety and efficacy of MitraClip (Abbott Vascular, Santa Clara, CA) to reduce mitral insufficiency in patients with ventricular FMR. In this population, MitraClip has shown to reduce mortality and HF hospitalizations, and to improve functional class and quality of life on top of stand-alone medical therapy [4], [5]. However, the use of transcatheter edge-to-edge repair (TEER) in patients with AFMR is poorly studied. Our aim was to address clinical and echocardiographic outcomes in patients with AFMR undergoing transcatheter edge-to-edge mitral valve repair with MitraClip compared to those with ventricular FMR (VFMR), PMR or mixed MR (MMR).
Section snippets
Methods
The Spanish MitraClip multicenter registry prospectively included all consecutive patients with symptomatic grade 3+ or 4+ MR undergoing TEER from June 2012 in 24 participating Institutions. In this observational study we evaluated the data from 1124 patients enrolled until July 21, 2020. Cases in which key information for screening of AFMR was missing (n = 33, 3.0%) and those with history of failed prior annuloplasty (n = 17, 1.5%) were excluded (Fig. 1).
Fig. 1 shows the screening flow chart.
Results
Overall, 1074 were analyzed in this report (Fig. 1). Patients with organic MV disease were classified as PMR or MMR (n = 402, 37.4%) and the rest of them were grouped as FMR (n = 672, 62.6%). Among patients with FMR, 48 (4.5%) subjects met criteria for AFMR.
Table 1 shows the baseline characteristics of the included cohort grouped by MR etiology. Patients with AFMR were significantly older (p < 0.001), more frequently women (p < 0.001) and had a higher body mass index (p = 0.006), as well as a
Discussion
To the best of our knowledge, this is the first multicenter registry to address clinical and echocardiographic outcomes of AFMR after TEER in the real-world setting. The main findings of our study were the following: 1) the prevalence of “pure” AFMR was low in our series; 2) MVA dilatation was a constant finding in this population; 3) TMVR effectively reduced AFMR with similar recurrence rates at 12-month follow-up vs VFMR or PMR/MMR; 4) After TEER, patients with AFMR showed an improvement in
Statement
All authors take responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.
Funding source
The website database and statistical analyses were supported by an unrestricted grant from Abbott Vascular.
Declaration of Competing Interest
Rodrigo Estevez-Loureiro is a consultant and proctor for Abbott Vascular. Dabit Arzamendi is a consultant and proctor for Abbott Vascular. Xavier Freixa is a consultant and proctor for Abbott Vascular. Luis Nombela-Franco is a consultant and proctor for Abbott Vascular. Garrote-Coloma is proctor for Abbott Vascular. Ignacio Cruz-González is proctor for Abbott Vascular. Juan Horacio Alonso-Briales is a consultant and proctor for Abbott Vascular. Isaac Pascual is proctor for Abbott Vascular. The
References (23)
- et al.
Basic mechanisms of mitral regurgitation
Can. J. Cardiol.
(2014) - et al.
Subtypes of atrial functional mitral regurgitation: imaging insights into their mechanisms and therapeutic implications
JACC Cardiovasc. Imaging
(2020) - et al.
Atrial functional mitral regurgitation: JACC review topic of the week
J. Am. Coll. Cardiol.
(2019) - et al.
Health status after transcatheter mitral-valve repair in heart failure and secondary mitral regurgitation: COAPT trial
J. Am. Coll. Cardiol.
(2019) - et al.
Evidence of atrial functional mitral regurgitation due to atrial fibrillation: reversal with arrhythmia control
J. Am. Coll. Cardiol.
(2011) - et al.
Mitral annular and left ventricular dynamics in atrial functional mitral regurgitation: a three-dimensional and speckle-tracking echocardiographic study
J. Am. Soc. Echocardiogr.
(2019) - et al.
Percutaneous edge-to-edge repair for atrial functional mitral regurgitation: a real-time 3-dimensional transesophageal echocardiography study
JACC Cardiovasc. Imaging
(2019) - et al.
Effect of transcatheter mitral annuloplasty with the cardioband device on 3-dimensional geometry of the mitral annulus
Am. J. Cardiol.
(2016) - et al.
Functional regurgitation of atrioventricular valves and atrial fibrillation: an elusive pathophysiological link deserving further attention
J. Am. Soc. Echocardiogr.
(2020) - et al.
Postprocedural changes of tricuspid regurgitation after MitraClip therapy for mitral regurgitation
J. Am. Cardiol.
(2017)
Cited by (17)
Mitral Transcatheter Edge-to-Edge Repair in Patients With Atrial Functional Mitral Regurgitation
2024, Journal of the American College of CardiologyImpact of Transcatheter Edge-to-Edge Mitral Valve Repair on Atrial Functional Mitral Regurgitation from the GIOTTO Registry
2024, American Journal of CardiologyHeart Failure and Secondary Mitral Regurgitation: A Contemporary Review
2023, Journal of the Society for Cardiovascular Angiography and InterventionsImplications of the Mitral Leaflet Coaptation Pattern on Clinical Outcomes in Patients With Functional Mitral Regurgitation
2023, American Journal of CardiologyTranscatheter Mitral Valve Repair Versus Transcatheter Mitral Valve Replacement in Patients with Mitral insufficiency
2023, Archives of Medical ResearchIncidence and causal association of functional atrial mitral regurgitation in HFpEF
2023, Hellenic Journal of CardiologyCitation Excerpt :Catheter-based intervention (MitraClip) theoretically may prove to be effective and a useful treatment choice, but it has to be proved by studies, which for the time being are limited and with small number of patients involved.42,43 Nevertheless, the results of these studies indicate that transcatheter MV repair is the interventional method of choice, especially in elderly patients.44,45,46 In summary, it seems that presently, the more appropriate noninterventional therapeutical approach for AFMR is prevention of LA dilatation and early treatment of AF.